Ruben Mesa/vjhemonc.com
Mar 12, 2025, 10:16
Ruben Mesa: Pelabresib plus Ruxolitinib for JAKi naive Myelofibrosis
Ruben Mesa, President and Executive Director of Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center, shared an article by Raajit K. Rampal, et al. on LinkedIn:
“Honored to have joined many wonderful colleagues in these important PhaseIII trial data for combination Pelabresib plus Ruxolitinib for JAKi naive myelofibrosis.”
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.
Authors: Raajit K. Rampal, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 11:10
Apr 20, 2025, 11:07
Apr 20, 2025, 11:06
Apr 20, 2025, 10:58
Apr 20, 2025, 10:56
Apr 20, 2025, 10:06